{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:13:53Z","timestamp":1788480833451,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T00:00:00Z","timestamp":1631491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>Rapid relapses after successful withdrawal occur even in apparently motivated benzodiazepine (BZD)-dependent patients. Regardless of known personality or biological (re-adaptation) issues, the aim of this open-label, single-arm, seminaturalistic study was to search for any detoxification errors contributing to failures.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The data came from 350 inpatients. Based on serum-BZD evolution criteria, the procedure was divided into four stages: substitution, accumulation, elimination and post-elimination observation. After switching the patients to a long-acting substitute (diazepam), to prevent data falsification due to unwanted overaccumulation, the doses were expeditiously reduced under laboratory feedback until accumulation stopped. With the start of effective elimination, the tapering rate slowed and was individually adjusted to the patient\u2019s current clinical state. The tracking of both serum-BZD concentration and the corresponding intensity of withdrawal symptoms was continued throughout the entire elimination phase, also following successful drug withdrawal. Detoxification was concluded only after the patient's post-elimination stabilization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Regardless of various initial serum-BZD concentration levels and the customized dose-reduction rate, and despite the novel lab-driven actions preventing initial overaccumulation, elimination was systematically proven to be protracted and varied within the 2- to 95-day range after the final dose. Within this period, withdrawal syndrome culminated several times, with varying combinations of symptoms. The last crisis occurrence (typically 2\u20133\u00a0weeks after withdrawal) correlated with the final serum-BZD elimination. The factors that prolonged elimination and delayed the final crisis were patient age, duration of addiction, adjunct valproate medication and elimination stage start parameters growing with former overaccumulation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The low-concentration detoxification stage is critical for patients\u2019 confrontations with recurring withdrawal symptoms. Underestimated elimination time following drug withdrawal and premature conclusions of detoxification expose patients to unassisted withdrawal crises. Concentration tracking defines proper limits for medical assistance, preventing early relapses.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00228-021-03205-x","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T09:35:32Z","timestamp":1631525732000},"page":"101-110","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Delayed crises following benzodiazepine withdrawal: deficient adaptive mechanisms or simple pharmacokinetics? Detoxification assisted by serum-benzodiazepine elimination tracking"],"prefix":"10.1007","volume":"78","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0664-1901","authenticated-orcid":false,"given":"Anna","family":"Basi\u0144ska-Szafra\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,13]]},"reference":[{"key":"3205_CR1","doi-asserted-by":"publisher","unstructured":"Denis C, Fats\u00e9as M, Lavie E, Auriacombe M (2006) Pharmacological interventions for benzodiazepine mono-dependence management in outpatient settings. Cochrane Database of Syst Rev, Issue 3, Art. No. CD005194. https:\/\/doi.org\/10.1002\/14651858.CD005194.pub2. Accessed: 15 June 2020.","DOI":"10.1002\/14651858.CD005194.pub2"},{"key":"3205_CR2","doi-asserted-by":"publisher","unstructured":"Baandrup L, Ebdrup BH, Rasmussen J\u00d8, Lindschou J, Gluud C, Glenth\u00f8j BY (2018) Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users (Review). Cochrane Database of Syst Rev Issue 3. Art. No.: CD011481. https:\/\/doi.org\/10.1002\/14651858.CD011481.pub2","DOI":"10.1002\/14651858.CD011481.pub2"},{"issue":"5","key":"3205_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1177\/2045125317753340","volume":"8","author":"D Fluyau","year":"2018","unstructured":"Fluyau D, Revadigar N, Manobianco BE (2018) Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology 8(5):147\u2013168","journal-title":"Therapeutic Advances in Psychopharmacology"},{"key":"3205_CR4","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","volume":"376","author":"M Soyka","year":"2017","unstructured":"Soyka M (2017) Treatment of benzodiazepine dependence. N Engl J Med 376:1147\u20131157. https:\/\/doi.org\/10.1056\/NEJMra1611832","journal-title":"N Engl J Med"},{"issue":"2","key":"3205_CR5","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/jcm7020020","volume":"7","author":"J Guina","year":"2018","unstructured":"Guina J, Merrill B (2018) Benzodiazepines II: waking up on sedatives: Providing optimal care when Inheriting benzodiazepine prescriptions in transfer patients. J Clin Med 7(2):20. https:\/\/doi.org\/10.3390\/jcm7020020","journal-title":"J Clin Med"},{"issue":"1\u20132","key":"3205_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/0740-5472(91)90023-4","volume":"8","author":"H Ashton","year":"1991","unstructured":"Ashton H (1991) Protracted withdrawal syndromes from benzodiazepines. J Subst Abuse Treat 8(1\u20132):19\u201328. https:\/\/doi.org\/10.1016\/0740-5472(91)90023-4","journal-title":"J Subst Abuse Treat"},{"key":"3205_CR7","unstructured":"Center for Substance Abuse Treatment (2010) Protracted Withdrawal. Substance Abuse Treatment Advisory, Vol. 9, Issue 1. https:\/\/store.samhsa.gov\/product\/protracted-withdrawal\/SMA10-4554. Accessed 15 Dec 2020"},{"issue":"13","key":"3205_CR8","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1177\/1049732317728053","volume":"27","author":"AM Fixsen","year":"2017","unstructured":"Fixsen AM, Ridge D (2017) Stories of Hell and Healing: Internet Users\u2019 Construction of Benzodiazepine Distress and Withdrawal. Qual Health Res 27(13):2030\u20132041. https:\/\/doi.org\/10.1177\/1049732317728053","journal-title":"Qual Health Res"},{"issue":"Suppl 1","key":"3205_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.neuropharm.2004.06.020","volume":"47","author":"G Aston-Jones","year":"2004","unstructured":"Aston-Jones G, Harris GC (2004) Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 47(Suppl 1):167\u2013179","journal-title":"Neuropharmacology"},{"issue":"Suppl 1","key":"3205_CR10","first-page":"18","volume":"56","author":"GF Koob","year":"2008","unstructured":"Koob GF (2008) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56(Suppl 1):18\u201331","journal-title":"Neuropharmacology"},{"key":"3205_CR11","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1124\/jpet.111.183285","volume":"339","author":"MM Reidenberg","year":"2011","unstructured":"Reidenberg MM (2011) Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 339:324\u2013328. https:\/\/doi.org\/10.1124\/jpet.111.183285","journal-title":"J Pharmacol Exp Ther"},{"issue":"6292","key":"3205_CR12","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1136\/bmj.283.6292.643","volume":"283","author":"H P\u00e9tursson","year":"1981","unstructured":"P\u00e9tursson H, Lader MH (1981) Withdrawal from long-term benzodiazepine treatment. BMJ 283(6292):643\u2013645. https:\/\/doi.org\/10.1136\/bmj.283.6292.643","journal-title":"BMJ"},{"key":"3205_CR13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/0376-8716(91)90049-5","volume":"29","author":"PM Brenner","year":"1991","unstructured":"Brenner PM, Wolf B, Rechlin T, Kauert G, R\u00fcther E, Hippius H (1991) Benzodiazepine dependence: detoxification under standardized conditions. Drug Alcohol Depend 29:195\u2013204. https:\/\/doi.org\/10.1016\/0376-8716(91)90049-5","journal-title":"Drug Alcohol Depend"},{"key":"3205_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1136\/bmj.291.6497.688","volume":"291","author":"AC Higgitt","year":"1985","unstructured":"Higgitt AC, Lader MH, Fonagy P (1985) Clinical management of benzodiazepine dependence. BMJ 291:688\u2013690","journal-title":"BMJ"},{"key":"3205_CR15","unstructured":"Ashton CH (2002) Slow withdrawal schedules. In: Benzodiazepines: how they work and how to withdraw. The Ashton manual (rev. version 2013). https:\/\/www.benzo.org.uk\/manual\/bzsched.htm Accessed 15 Dec\u00a02020"},{"key":"3205_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/09595230100100615","volume":"22","author":"C McGregor","year":"2003","unstructured":"McGregor C, Machin A, White JM (2003) In-patient benzodiazepine withdrawal: comparison of fixed and symptom-triggered taper methods. Drug Alcohol Rev 22:175\u2013180","journal-title":"Drug Alcohol Rev"},{"key":"3205_CR17","first-page":"1","volume":"2","author":"F Frare","year":"2000","unstructured":"Frare F, Perugi G (2000) Managing benzodiazepine withdrawal. Heroin Addiction & Related Clinical Problems 2:1\u201318","journal-title":"Heroin Addiction & Related Clinical Problems"},{"key":"3205_CR18","first-page":"75","volume":"22","author":"A Basi\u0144ska-Starzycka","year":"2009","unstructured":"Basi\u0144ska-Starzycka A, Jamro\u017cy A, Habrat B (2009) Benzodiazepine discontinuation and withdrawal treatment \u2013 individualization of treatment based on using clinical assessment and pharmacokinetic monitoring. Alcoholism & Drug Addiction 22:75\u201386","journal-title":"Alcoholism & Drug Addiction"},{"key":"3205_CR19","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1111\/j.1360-0443.2011.03563.x","volume":"106","author":"M Lader","year":"2011","unstructured":"Lader M (2011) Benzodiazepines revisited - will we ever learn? Addiction 106:2086\u20132109. https:\/\/doi.org\/10.1111\/j.1360-0443.2011.03563.x","journal-title":"Addiction"},{"key":"3205_CR20","doi-asserted-by":"publisher","unstructured":"Lader M, Tylee A, Donoghue J (2009) Withdrawing benzodiazepines in primary care. CNS Drugs 23(1):19\u201334. https:\/\/doi.org\/10.2165\/0023210-200923010-00002","DOI":"10.2165\/0023210-200923010-00002"},{"issue":"6424","key":"3205_CR21","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/bmj.288.6424.1135","volume":"288","author":"H Ashton","year":"1984","unstructured":"Ashton H (1984) Benzodiazepine withdrawal: an unfinished story. BMJ 288(6424):1135\u20131140. https:\/\/doi.org\/10.1136\/bmj.288.6424.1135","journal-title":"BMJ"},{"key":"3205_CR22","doi-asserted-by":"publisher","unstructured":"Miller F, Nulsen J (1979) SIngle case study. Diazepam (Valium) detoxification. J Nerv Ment Dis 167(10):637\u2013638. https:\/\/doi.org\/10.1097\/00005053-197910000-00010","DOI":"10.1097\/00005053-197910000-00010"},{"key":"3205_CR23","doi-asserted-by":"publisher","first-page":"e33","DOI":"10.1016\/j.forsciint.2012.06.018","volume":"222","author":"LW Storhaug","year":"2012","unstructured":"Storhaug LW, Enger A, Hjelmeland K, \u00d8iestad EL, Vindenes V (2012) Prolonged excretion of 7-aminoclonazepam in urine after repeated ingestion of clonazepam: A case report. Forensic Sci Int 222:e33\u2013e35. https:\/\/doi.org\/10.1016\/j.forsciint.2012.06.018","journal-title":"Forensic Sci Int"},{"key":"3205_CR24","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40360-015-0019-8","volume":"16","author":"AS Pollmann","year":"2015","unstructured":"Pollmann AS, Murphy AL, Bergman JC, Gardner DM (2015) Deprescribing the benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 16:19. https:\/\/doi.org\/10.1186\/s40360-015-0019-8","journal-title":"BMC Pharmacol Toxicol"},{"key":"3205_CR25","doi-asserted-by":"publisher","unstructured":"Basi\u0144ska-Szafra\u0144ska A (2021) Metabolic diversity as a reason for unsuccessful detoxification from benzodiazepines. The rationale for serum BZD concentration monitoring. Eur J Clin Pharmacol 77, 795\u2013808. https:\/\/doi.org\/10.1007\/s00228-020-03048-y","DOI":"10.1007\/s00228-020-03048-y"},{"issue":"9","key":"3205_CR26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002881","volume":"95","author":"I Kacirova","year":"2016","unstructured":"Kacirova I, Grundmann M, Silhan P, Brozmanova H (2016) A case report of clonazepam dependence: utilization of therapeutic drug monitoring during withdrawal period. Medicine (Baltimore) 95(9):e2881. https:\/\/doi.org\/10.1097\/MD.0000000000002881","journal-title":"Medicine (Baltimore)"},{"key":"3205_CR27","doi-asserted-by":"publisher","unstructured":"Oliveras C, Fortea A, Espinosa L, Barrio P, Lligo\u00f1a A, Balcells-Olivero M (2018) \u201cDiazepam loading\u201d: Can a strategy for preventing alcohol withdrawal be used to treat benzodiazepine use disorder? Adicciones 30(2):155\u2013157. https:\/\/doi.org\/10.20882\/adicciones.1058.","DOI":"10.20882\/adicciones.1058"},{"key":"3205_CR28","unstructured":"Ashton CH (2007) Benzodiazepines Equivalence Table (revised version). https:\/\/www.benzo.org.uk\/bzequiv.htm. Accessed December 15, 2020."},{"key":"3205_CR29","unstructured":"World Health Organisation (1993) The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic criteria for research. F10-F19 Mental and behavioural disorders due to psychoactive substance use. https:\/\/www.who.int\/substance_abuse\/terminology\/ICD10ResearchDiagnosis.pdf?ua=1, pp.8\u20139"},{"key":"3205_CR30","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/00004714-198912000-00005","volume":"9","author":"UE Busto","year":"1989","unstructured":"Busto UE, Sykora K, Sellers E (1989) A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 9:412\u2013416","journal-title":"J Clin Psychopharmacol"},{"key":"3205_CR31","unstructured":"Roche Diagnostics (2015) Serum Benzodiazepines (SBENZ) #20766690322, Method sheet v.8. Roche Diagnostics GmbH, Mannheim, https:\/\/pim-eservices.roche.com\/LifeScience\/Document\/2ca042f2-2d7f-e511-bbab-00215a9b3428. Accessed 15 Jan\u00a02021"},{"key":"3205_CR32","unstructured":"Statsoft Inc. (2017) Statistica 13.3.0, https:\/\/www.statsoft.pl\/statistica_13_3\/. Accessed: 15 Dec\u00a02020"},{"key":"3205_CR33","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2165\/00003088-197803010-00005","volume":"3","author":"M Mandelli","year":"1978","unstructured":"Mandelli M, Tognoni G, Garattini S (1978) Clinical pharmacokinetics of diazepam. Clin Pharmacokinet 3:72\u201391","journal-title":"Clin Pharmacokinet"},{"key":"3205_CR34","unstructured":"Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group (2017) Benzodiazepines and z-drugs. In: Drug misuse and dependence: UK guidelines on clinical management. London, Department of Health (Chapter 4.10.1, p.121).https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/673978\/clinical_guidelines_2017.pdf. Accessed 15 Dec\u00a02020"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03205-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-021-03205-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-021-03205-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,3]],"date-time":"2022-01-03T18:17:30Z","timestamp":1641233850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-021-03205-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,13]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["3205"],"URL":"https:\/\/doi.org\/10.1007\/s00228-021-03205-x","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,13]]},"assertion":[{"value":"10 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The methodology of the study was approved by the Bioethical Committee at the Institute of Psychiatry and Neurology of Warsaw (Ethics approval no 18\/2018).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}